By Skyepharma Production…
To get in touch with Skyepharma Production S.A.S., simply fill out the form below.
Subscribe to Supplier
Skyepharma CDMO makes debut at Nordic Life Science Days
Saint-Quentin-Fallavier, France: – Oral dosage specialist Skyepharma Production S.A.S. (Skyepharma) will make its first-ever appearance at Scandinavia’s leading pharma industry event, the Nordic Life Science Days partnering conference.
For 2023, the Tenth Anniversary NLS Days will be hosted for the first time in Copenhagen.
Oral solid and development partnering opportunities
While not exhibiting, Skyepharma will be an active participant in the conference’s networking forums, led by its Chief Scientific Officer Dr. Frederic Checot and Chief Business Officer Dr. Laurent Rigaudeau.
The Skyepharma team will seek new partnering opportunities that take advantage of its advanced development and manufacturing capabilities in oral solid dose (OSD) pharma products. These include the ability to handle the highly active HPAPI ingredients used in oncology drugs.
They will also present Skyepharma’s various innovation programs to possible academic and industrial partners.
Experts in R&D
Frederic Checot commented: “We are very excited to be attending NLSDays for the first time and have this excellent opportunity to introduce our brand new expert R&D, clinical and commercial capabilities for oncology and OEB4/5 oral solids to a North European audience.”
Laurent Rigaudeau added: “For any pharma and nutraceutical company seeking a CDMO partner with strong development capabilities in complex solid forms and premium supplements we can offer a very comprehensive portfolio of capabilities that includes multilayer tablet, tab-in-tab, controlled release and enhanced bioavailability expertise, as well as tablets in capsules, along with agility, high quality assurance, advanced development capabilities and a one stop shop, end-to-end, business model.”
About Skyepharma Production
Skyepharma is an independent French pharmaceutical CDMO, 100% owned by its management team and Bpifrance. Skyepharma is an expert CDMO specialised in the formulation, development and manufacturing of complex oral solid forms (OSD), with an extensive and specific expertise and proprietary technologies on modified release products.
Skyepharma is based in Saint-Quentin-Fallavier, France. The current factory, dedicated to its OSD activity, occupies 22,000m2, on a 60,000m2 piece of land. Skyepharma has decided to allocate a portion of the available land (more than 10,000m2) to establish its SkyeHub Bioproduction, an innovative model designed to offer clinical and commercial production capacities to biotech companies. This SkyeHub model includes the construction of dedicated buildings, with specifically designed surfaces and premises, together with transverse support services such as quality, maintenance, batch release, etc.
Learn more at: www.skyepharma.com
About Nordic Life Science Days 2023
Nordic Life Science Days (NLSDays) is Scandinavia’s largest partnering conference for the global Life Science industries.
The event is aimed at leading decision makers from the whole Life Sciences sector, including not only biotech, pharma and Medtech but also finances, research, policy and regulatory authorities. The event has grown steadily over the past three years, from 650 participants in 2013 to some 1,500 at last year’s conference.
The Tenth Anniversary 2023 NLSDays meeting is a two-day event opening November 29 at the Bella Center in Copenhagen, the series’ first visit to Denmark.
Along with networking sessions powered by the BIO One-On-One Partnering™ system, the conference will also feature fireside chats, super sessions focusing on success stories from the Nordic life science sector, company presentations forum, an Innovative Posters competition, and the Nordic Stars pitch competition for up-and-coming innovators, competing for attractive prize packages.
The event is organised by Sweden Bio and BioNordic, with more information at: www.nlsdays.com
Click on Skyepharma, Center of Excellence to watch corporate presentation.